Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Blood (2021) 137 (15): 2070–2084.

https://doi.org/10.1182/blood.2019004509

Published: 2021

Includes: Supplemental data

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Blood (2020) 136 (Supplement 1): 53.

https://doi.org/10.1182/blood-2020-140477

Published: 2020

Journal Articles

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Gregor Eisenwort, MD PhD, Alexandra Keller, Michael Willmann, Irina Sadovnik, Greiner Georg, MD PhD, Karoline V. Gleixner, MD, Daniel Ivanov, MSc, Daniela Berger, Gabriele Stefanzl, Christiana Winding, DVM, Gregor Hoermann, Wolfgang R. Sperr, MD, Heinz Sill, MD, Peter Bettelheim, MD, Klaus Geissler, MD, Michael W. Deininger, Thomas Rülicke, Peter Valent, MD

Blood (2019) 134 (Supplement_1): 4223.

https://doi.org/10.1182/blood-2019-122530

Published: 2019

Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2018-99-116525

Published: 2018

Journal Articles

BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph + CML

Barbara Peter, Gregor Eisenwort, Alexandra Keller, Karin Bauer, Daniela Berger, Irina Sadovnik, Gabriele Stefanzl, Gregor Hoermann, Dominik Wolf, Zdenek Racil, Jiří Mayer, Johannes Zuber, Wolfgang R. Sperr, Georg E. Winter, Michael Willmann, Thomas Rülicke, Peter Valent

Blood (2018) 132 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2018-99-111126

Published: 2018

Journal Articles

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

Blood (2018) 132 (18): 1936–1950.

https://doi.org/10.1182/blood-2018-02-833582

Published: 2018

Includes: Supplemental data

Journal Articles

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Georg Greiner, Nadine Witzeneder, Angelika Berger, Klaus Schmetterer, Gregor Eisenwort, Ana-Iris Schiefer, Simone Roos, Theresia Popow-Kraupp, Leonhard Müllauer, Johannes Zuber, Veronika Sexl, Lukas Kenner, Wolfgang R. Sperr, Peter Valent, Matthias Mayerhofer, Gregor Hoermann

Blood (2017) 129 (3): 371–382.

https://doi.org/10.1182/blood-2016-09-739003

Published: 2017

Includes: Supplemental data

Journal Articles

Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC

Irina Sadovnik, MSc, Harald Herrmann, MD, Katharina Blatt, MSc, PhD, Gregor Eisenwort, MD PhD, Niklas Mueller, MD, Gabriele Stefanzl, Gregor Hoermann, Susanne Herndlhofer, Karin Bauer, PhD, Barbara Peter, DVM, Rene Gaupmann, MD, Axel Schulenburg, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2016) 128 (22): 4234.

https://doi.org/10.1182/blood.V128.22.4234.4234

Published: 2016

Journal Articles

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

Karoline V Gleixner, MD, Mathias A Schneeweiss, MD, Harald Herrmann, MD, Katharina Blatt, MSc, PhD, Daniela Berger, Gregor Eisenwort, MD PhD, Georg Greiner, MD, Konstantin Byrgazov, PhD, Gregor Hoermann, Marina Konopleva, MD PhD, Islam Waliul, Patrick T Gunning, PhD, Hiroshi Maeda, PhD, Richard Moriggl, PhD, Michael W. Deininger, MD PhD, Thomas Lion, PhD, Michael Andreeff, MD PhD, Peter Valent, MD

Blood (2016) 128 (22): 4241.

https://doi.org/10.1182/blood.V128.22.4241.4241

Published: 2016

Journal Articles

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

Niklas Mueller, MD, Daniel Wicklein, PhD, Gregor Eisenwort, MD PhD, Juliana Schwaab, MD, Mohamad Jawhar, MD, Alexandra Boehm, MD, Harald Herrmann, MD, Gabriele Stefanzl, Gregor Hoermann, Wolfgang R. Sperr, MD, Michel Arock, PharmD,PhD, Andreas Reiter, MD, Udo Schumacher, MD, Peter Valent, MD

Blood (2016) 128 (22): 1955.

https://doi.org/10.1182/blood.V128.22.1955.1955

Published: 2016

Journal Articles

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Katharina Blatt, Sabine Cerny-Reiterer, Juliana Schwaab, Karl Sotlar, Gregor Eisenwort, Gabriele Stefanzl, Gregor Hoermann, Matthias Mayerhofer, Mathias Schneeweiss, Sylvia Knapp, Thomas Rülicke, Emir Hadzijusufovic, Karin Bauer, Dubravka Smiljkovic, Michael Willmann, Andreas Reiter, Hans-Peter Horny, Peter Valent

Blood (2015) 126 (26): 2832–2841.

https://doi.org/10.1182/blood-2015-03-637728

Published: 2015

Includes: Supplemental data

Journal Articles

Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML

Barbara Peter, DVM, Gregor Eisenwort, Gabriele Stefanzl, Daniela Berger, Wolfgang R Sperr, MD, Johannes Zuber, MD PhD, Peter Valent, MD

Blood (2015) 126 (23): 1571.

https://doi.org/10.1182/blood.V126.23.1571.1571

Published: 2015

Journal Articles

Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia

Gregor Eisenwort, MD PhD, Barbara Peter, D.V.M., Katharina Blatt, MSc, PhD, Sabine Cerny-Reiterer, DVM, Gregor Hoermann, MD PhD, Irina Sadovnik, MSc, Martin Bilban, MD, Thomas Rülicke, D.V.M., Michael Willmann, D.V.M., Juliana Schwaab, MD, Andreas Reiter, MD, Wolfgang R Sperr, MD, Christine Mannhalter, PhD, Peter Valent, MD

Blood (2014) 124 (21): 817.

https://doi.org/10.1182/blood.V124.21.817.817

Published: 2014

Journal Articles

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Blood (2014) 124 (21): 1800.

https://doi.org/10.1182/blood.V124.21.1800.1800

Published: 2014

Journal Articles

Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS

Karin Bauer, PhD, Sigrid Machherndl-Spandl, MD, Susanne Suessner, MSc, Martin Danzer, MSc, Johannes Pröll, PhD, Jeroen Lauf, Gregor Eisenwort, MD PhD, Wolfgang R. Sperr, MD, Hans-Ulrich Klein, PhD, Gregor Hoermann, MD PhD, Norman Häfner, PhD, Marie Bene, PharmSciD, PhD, Uwe Platzbecker, MD, Ansgar Weltermann, MD, Christian Gabriel, MD, Ulrich Germing, Peter Bettelheim, MD, Peter Valent, MD

Blood (2014) 124 (21): 1570.

https://doi.org/10.1182/blood.V124.21.1570.1570

Published: 2014

Journal Articles

Abnormal Expression Of The Major Coxsackie-Adenovirus Receptor CAR On Immature Dysplastic CD105+ Erythroid Progenitor Cells In Patients With MDS and Related Bone Marrow Neoplasms

Sigrid Machherndl-Spandl, MD, Susanne Suessner, Martin Danzer, Johannes Proell, Christian Gabriel, MD, Jeroen Lauf, Gregor Eisenwort, Wolfgang R Sperr, M.D., Peter Valent, Hans-Ulrich Klein, PhD, Marie-Christine Bene, PharmSciD, PhD, Ulrich Germing, MD, Uwe Platzbecker, MD, PhD, Ansgar Weltermann, MD, Otto Zach, PhD, Peter Bettelheim, MD

Blood (2013) 122 (21): 2818.

https://doi.org/10.1182/blood.V122.21.2818.2818

Published: 2013

Journal Articles

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

Ghaith Wedeh, Emir Hadzijusufovic, DVM, Sabine Cerny-Reiterer, D.V.M, Harald Herrmann, M.D., Katharina Blatt, MSc, Ph.D., Gregor Eisenwort, M.D., Ph.D, Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Leonhard Müllauer, M.D., Christopher R. Vakoc, M.D., Ph.D., James E Bradner, MD, Hans-Peter Horny, MD, Michael Willmann, D.V.M., Johannes Zuber, MD, Michel Arock, PharmD, Ph.D, Peter Valent

Blood (2013) 122 (21): 3747.

https://doi.org/10.1182/blood.V122.21.3747.3747

Published: 2013

Journal Articles

Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants

Sabine Cerny-Reiterer, D.V.M, Katharina Blatt, MSc, Ph.D., Harald Herrmann, M.D., Gregor Eisenwort, M.D., Ph.D, Susanne Herndlhofer, Heinz Sill, M.D., Werner Rabitsch, MD, Christine Mannhalter, M.D., Alexander Hauswirth, M.D., Wolfgang R Sperr, M.D., Ulrich Jaeger, Peter Valent

Blood (2013) 122 (21): 1654.

https://doi.org/10.1182/blood.V122.21.1654.1654

Published: 2013

Journal Articles

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

Hadzijusufovic Emir, DVM, Karin Albrecht-Schgoer, PhD, Kilian Huber, PhD, Florian Grebien, PhD, Gregor Eisenwort, MD, PhD, Wilfried Schgoer, MD, PhD, Christoph Kaun, Susanne Herndlhofer, Markus Theurl, PhD, Sabine Cerny-Reiterer, D.V.M., Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Rix Uwe, PhD, Johann Wojta, PhD, Dominik Wolf, MD, Giulio Superti-Furga, PhD, Rudolf Kirchmair, MD, Peter Valent

Blood (2013) 122 (21): 257.

https://doi.org/10.1182/blood.V122.21.257.257

Published: 2013

NARROW

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph + CML

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML

Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS

Abnormal Expression Of The Major Coxsackie-Adenovirus Receptor CAR On Immature Dysplastic CD105+ Erythroid Progenitor Cells In Patients With MDS and Related Bone Marrow Neoplasms

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only